Stock PROC PROCAPS GROUP S.A.
Add to a list
To use this feature you must be a member
Log inSign up

Ratings Procaps Group S.A.

Equities

PROC

LU2376511205

Market Closed - Nasdaq
Other stock markets
 04:30:00 2024-05-01 pm EDT 		5-day change 1st Jan Change
2.775 USD +5.92% Intraday chart for Procaps Group S.A. +0.91% -31.82%
Mar. 04 Procaps Group S.A. Announces Formation of Strategic Committee to Explore Value Creation Alternatives CI
Mar. 04 Procaps Group Announces Formation of Strategic Committee to Explore Value Creation Alternatives CI

Strengths

  • Its low valuation, with P/E ratio at 5.78 and 7.3 for the ongoing fiscal year and 2024 respectively, makes the stock pretty attractive with regard to earnings multiples.
  • For the past year, analysts covering the stock have been revising their EPS expectations upwards in a significant manner.
  • The average target price set by analysts covering the stock is above current prices and offers a tremendous appreciation potential.
  • The divergence of price targets given by the various analysts who make up the consensus is relatively low, suggesting a consensus method of evaluating the company and its prospects.

Weaknesses

  • The company's earnings growth outlook lacks momentum and is a weakness.
  • The company appears highly valued given the size of its balance sheet.
  • For the last twelve months, sales expectations have been significantly downgraded, which means that less important sales volumes are expected for the current fiscal year over the previous period.
  • Over the past twelve months, analysts' opinions have been revised negatively.
  • The company's earnings releases usually do not meet expectations.

Ratings chart - Surperformance

Sector: Pharmaceuticals

1st Jan change Capi. Investor Rating ESG Refinitiv
PROCAPS GROUP S.A. Stock Procaps Group S.A.
-31.82% 296M -
ELI LILLY AND COMPANY Stock Eli Lilly and Company
+33.25% 704B
C+
NOVO NORDISK A/S Stock Novo Nordisk A/S
+28.59% 577B
B
JOHNSON & JOHNSON Stock Johnson & Johnson
-3.55% 348B
C+
MERCK & CO., INC. Stock Merck & Co., Inc.
+18.16% 327B
B-
ABBVIE INC. Stock AbbVie Inc.
+4.36% 288B
C+
ASTRAZENECA PLC Stock AstraZeneca PLC
+14.81% 234B
B+
NOVARTIS AG Stock Novartis AG
+4.93% 198B
B-
ROCHE HOLDING AG Stock Roche Holding AG
-9.78% 194B
A+
AMGEN INC. Stock Amgen Inc.
-3.69% 147B
C+
Investor Rating
Trading Rating
-
ESG Refinitiv
-

Financials

Sales growth
Earnings Growth
EBITDA / Sales
Profitability
Finances
-

Valuation

P/E ratio
EV / Sales
-
Price to Book
Price to Free Cash Flow
-
Yield
-

Momentum

1 year Revenue revision
4 months Revenue revision
7 days Revenue revision
1 year EPS revision
4 months EPS revision

Consensus

Analyst Opinion
Potential Price Target
4m Target Price Revision
4m Revision of opinion
-
12m Revision of opinion

Business Predictability

Analyst Coverage
Divergence of Estimates
-
Divergence of analysts' opinions
-
Divergence of Target Price
Earnings quality

Technical analysis

ST Timing
MT Timing
LT Timing
RSI
Bollinger Spread
Unusual volumes
  1. Stock Market
  2. Equities
  3. PROC Stock
  4. Ratings Procaps Group S.A.